» Articles » PMID: 28490031

A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D6)

Overview
Publisher Karger
Specialties Pharmacology
Psychiatry
Date 2017 May 11
PMID 28490031
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In a study aimed at identifying the items carrying information regarding the global severity of depression, the 6-item Hamilton Depression Rating Scale (HAM-D6) was derived from the original 17-item version of the scale (HAM-D17). Since then, the HAM-D6 has been used in a wide range of clinical studies. We now provide a systematic review of the clinimetric properties of HAM-D6 in comparison with those of HAM-D17 and the Montgomery Asberg Depression Rating Scale (MADRS).

Methods: We conducted a systematic search of the literature in PubMed, PsycInfo, and EMBASE databases in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Studies reporting data on the clinimetric validity of the HAM-D6 and either the HAM-D17 or MADRS in non-psychotic unipolar or bipolar depression were included in the synthesis.

Results: The search identified 681 unique records, of which 51 articles met the inclusion criteria. According to the published literature, HAM-D6 has proven to be superior to both HAM-D17 and MADRS in terms of scalability (each item contains unique information regarding syndrome severity), transferability (scalability is constant over time and irrespective of sex, age, and depressive subtypes), and responsiveness (sensitivity to change in severity during treatment).

Conclusions: According to the published literature, the clinimetric properties of HAM-D6 are superior to those of both the HAM-D17 and MADRS. Since the validity of HAM-D6 has been demonstrated in both research and clinical practice, using the scale more consistently would facilitate translation of results from one setting to the other.

Citing Articles

The risks of adverse events with mirtazapine for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis.

Kamp C, Petersen J, Faltermeier P, Juul S, Sillassen C, Siddiqui F BMC Psychiatry. 2025; 25(1):67.

PMID: 39844067 PMC: 11755810. DOI: 10.1186/s12888-024-06396-6.


The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.

Kamp C, Petersen J, Faltermeier P, Juul S, Siddiqui F, Moncrieff J Epidemiol Psychiatr Sci. 2024; 33:e51.

PMID: 39440379 PMC: 11561525. DOI: 10.1017/S2045796024000520.


Whole-brain turbulent dynamics predict responsiveness to pharmacological treatment in major depressive disorder.

Escrichs A, Sanz Perl Y, Fisher P, Martinez-Molina N, G-Guzman E, Frokjaer V Mol Psychiatry. 2024; 30(3):1069-1079.

PMID: 39256549 PMC: 11835742. DOI: 10.1038/s41380-024-02690-7.


Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis.

Kamp C, Petersen J, Faltermeier P, Juul S, Siddiqui F, Barbateskovic M BMJ Ment Health. 2024; 27(1.

PMID: 39093721 PMC: 10806869. DOI: 10.1136/bmjment-2023-300730.


A Case Series Study of Weekly or Fortnightly Transcranial Magnetic Stimulation (TMS) in Major Depressive Disorder.

Turnier-Shea Y, Peterson G, Rybak M, Pridmore S Brain Sci. 2024; 14(5).

PMID: 38790394 PMC: 11118001. DOI: 10.3390/brainsci14050415.